Posted: 8th February 2024 | Back to news feed

 Audevard Unveils a New Era in Joint Support with Ekyflex Arthro Evo

Audevard, a pioneer in equestrian innovation, proudly announces a groundbreaking leap in equine joint care with the launch of EKYFLEX ARTHRO EVO. This unparalleled solution is meticulously crafted to enhance the fluidity of a horse's stride while ensuring paramount protection for their joints.

Audevard's unwavering commitment to advancing equine joint health is evident in EKYFLEX ARTHRO EVO, featuring a groundbreaking formulation comprising a new generation of highly specific, concentrated ingredients. This marks a transformative shift in joint protection, expanding beyond the preservation of articular cartilage and synovial fluid to include the crucial subchondral bone. Scientific breakthroughs have enabled the extraction of new ingredients from natural sources, significantly enhancing the overall efficacy of the product.

This development is especially pertinent in light of ongoing discussions within the FEI about the potential addition of Methyl Sulphonyl Methane (MSM) to the list of prohibited substances for equines. The racing industry, represented by the British Horseracing Authority, has already taken this step. Acknowledging the necessity to stay ahead of potential regulatory changes, Audevard has made a proactive decision to eliminate MSM from EKYFLEX ARTHRO EVO, opting for Boswellia as a substitute. This strategic move not only positions Audevard as a leader in equine health but also ensures peace of mind for horse owners, pre-emptively addressing any issues that may arise down the line.

Developed by Audevard's expert veterinarians, the unique formula aligns seamlessly with equine physiology, excluding animal-based components, artificial colours, and minimising sugar content. The essential components of this formula include plant-based glucosamine, phytosterols from avocado and soy, proanthocyanidins from grape seed and skin extract, and Peptagen II® (a specific collagen precursor complex). This innovative and concentrated formula provides triple protection for the joints by preserving the subchondral bone and safeguarding cartilage and synovial fluid.

Furthermore, scientific evidence attests to the efficacy of EKYFLEX ARTHRO EVO. A 2023 study with 20 horses assessed gait symmetry before, during, and after a 30-day supplementation with EKYFLEX ARTHRO EVO (30g/day). The analysis revealed rapid and sustained improvement in gait symmetry, offering clear and strong evidence of the product's positive influence on equine gait and confirming its effectiveness in sustaining optimal joint health.

EKYFLEX ARTHRO EVO addresses the imperative need for protection against premature joint degradation in horses. Maintaining optimal physical capabilities, preserving performance, preventing irregular strides and improving the stride quality and regularity are pivotal to avoiding early retirement.


For more information and pricing details on EKYFLEX ARTHRO EVO, please visit the Audevard UK website;

EKYFLEX ARTHRO EVO 450g £49.90, 900g £86.90, 1.8kg £166.90, 4.5kg £373.90, to 12kg £943.90

The Equestrian Index newsfeed is compiled from articles submitted by advertising members and expresses the opinions of those members. Watsons Directories Ltd shall not be held liable for any inaccuracies or mis-statements therein.

Back To Top